Eugit develops novel tissue targeting therapies for complex diseases. The company leverages expertise in computational genomics and immunology to design precise therapeutic approaches. Their focus is on creating treatments that selectively engage specific biological targets within diseased tissues.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies face limitations in accessibility and effectiveness, particularly for solid tumors like breast, ovarian, and prostate cancers. Existing treatments may not be effective for all patients, and the development of personalized therapies can be complex and costly.
Solution
This startup is developing off-the-shelf immune cell-based therapies that utilize gamma delta T-cells to target and eliminate solid tumors. Gamma delta T-cells offer a unique approach to cancer immunotherapy due to their ability to recognize and kill cancer cells without prior sensitization. The company's therapies aim to provide a more accessible and effective treatment option for patients with breast, ovarian, and prostate cancers, overcoming the limitations of existing immunotherapies. By leveraging the inherent tumor-targeting capabilities of gamma delta T-cells, the startup seeks to create a readily available and scalable solution for a broad range of patients.
Target Audience
The primary target audience includes patients with breast, ovarian, and prostate cancers, as well as oncologists and medical professionals seeking more effective and accessible immunotherapy options.
Features
- Utilizes gamma delta T-cells for targeted cancer cell elimination.
- Off-the-shelf therapy for immediate patient availability.
- Focus on solid tumors, including breast, ovarian, and prostate cancers.
- Aims to overcome limitations of existing cancer immunotherapies.